SEC Form 4 · accession 0001250853-16-000156
IOVANCE BIOTHERAPEUTICS, INC. · IOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maria Fardis
Officer — President & CEO · Director
Period of report
Jun 1, 2016
Accepted (ET)
Jun 9, 2016 · 9:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001425205
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2016 | A | 550,000 | $0.00 | A | 550,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $5.87 | Jun 1, 2016 | A | 500,000 | A | — | Jun 1, 2026 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Consists of 550,000 restricted stock units that will vest as follows: (i) 137,500 restricted stock units will vest on June 1, 2017; (ii) 275,000 restricted stock units will vest upon the satisfaction of certain clinical trial milestones; and (iii) 137,500 restricted stock units will vest in equal monthly installments over the 36-month period following June 1, 2017, in each case, provided that the Reporting Person has been continuously employed with the Issuer on the respective dates.
- F2The option will vest as to 125,000 shares on June 1, 2017, and the remaining options shall vest in equal monthly installments over the next 36 months after June 1, 2017, provided the Reporting Person is still providing services to the Issuer on the respective dates.